Number of shares and votes in Medivir
Medivir AB announced an increase in its share count as of March 2021, following a directed issuance to Linc AB, adding 3,600,000 class B shares. The total share count now stands at 55,735,651, with corresponding voting rights. Medivir focuses on developing innovative cancer therapies, notably MIV-818 for liver cancer, alongside collaborations like Birinapant licensed to IGM Biosciences. The stock is traded under the ticker MVIR on Nasdaq Stockholm.
- Increase of 3,600,000 class B shares enhances capital.
- Focus on innovative drug development addressing cancer needs.
- Collaboration with IGM Biosciences for birinapant could expand market reach.
- None.
STOCKHOLM, March 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during March 2021 as a result of the previously announced directed issue to Linc AB which in total resulted in an increase of 3,600,000 class B shares.
Today, the last trading day of the month, there are in total 55,735,651 shares in Medivir, of which all are class B shares with in total 55,735,651 corresponding voting rights.
For additional information, please contact
Yilmaz Mahshid, CEO
Telephone: +46 8 5468 3100
E-mail: yilmaz.mahshid@medivir.com
Magnus Christensen, CFO
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
This information is such information that Medivir AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication on 31 March 2021 at 08:30 CEST through the agency of the contact persons set out above.
Medivir in brief
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medivir/r/number-of-shares-and-votes-in-medivir,c3317921
The following files are available for download:
Press release (PDF) |
View original content:http://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-medivir-301259266.html
SOURCE Medivir
FAQ
What is the current share count for Medivir AB (MVRBF)?
What led to the increase in shares for Medivir AB (MVRBF)?
What is Medivir AB's primary focus in drug development?
Where is Medivir AB (MVRBF) listed?
What is the ticker symbol for Medivir AB?
